National Health Investors financials
$66.66−0.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $351.7M | $311.5M | $298.0M | $278.2M | $298.7M | $307.2M | $294.2M | $280.8M | $265.2M | $232.4M |
| Gross profit | $351.7M | $311.5M | $298.0M | $278.2M | $298.7M | $307.2M | $294.2M | $280.8M | $265.2M | $232.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $227.6M | $207.0M | $196.3M | $142.5M | $186.2M | $198.3M | $193.7M | $190.3M | $184.3M | $145.8M |
| Net income | $142.0M | $137.9M | $135.6M | $66.4M | $111.8M | $185.1M | $160.5M | $154.3M | $159.4M | $151.5M |
| Net margin | 40.4% | 44.3% | 45.5% | 23.9% | 37.4% | 60.3% | 54.5% | 55.0% | 60.1% | 65.2% |
| Diluted EPS | $3.02 | $3.13 | $3.13 | $1.48 | $2.44 | $4.14 | $3.67 | $3.67 | $3.87 | $3.87 |
| EBITDA | $313.0M | $281.4M | $268.8M | $214.0M | $268.0M | $282.7M | $271.8M | $262.4M | $252.1M | $205.8M |
| Operating cash flow | $236.6M | $207.8M | $184.4M | $194.2M | $210.9M | $232.1M | $241.0M | $207.9M | $198.1M | $176.6M |
| Free cash flow | $216.6M | $188.0M | $173.0M | $194.2M | $207.3M | $115.4M | $3.8M | $60.2M | $22.3M | -$226.3M |
| Diluted shares | 47.1M | 44.1M | 43.4M | 44.8M | 45.7M | 44.7M | 43.7M | 42.1M | 41.2M | 39.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.6M | $24.3M | $22.3M | $19.3M | $37.4M | $43.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $1.16B | $1.15B | $1.14B | $1.15B | $1.24B | $1.50B |
| Total assets | $2.80B | $2.61B | $2.49B | $2.51B | $2.84B | $3.12B |
| Total liabilities | $1.26B | $1.23B | $1.21B | $1.22B | $1.32B | $1.60B |
| Shareholders' equity | $1.53B | $1.38B | $1.26B | $1.28B | $1.52B | $1.52B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology